Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40
Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.
Stocks · News reference
BlossomHill Therapeutics Announces Updated Data From Ongoing Phase 1/2 SOLARA Trial Of BH-30643 In NSCLC Patients With Secondary EGFR Resistance Mutations Such As EGFR C797S
45% objective response rate and 88% disease control rate observed in patients with EGFR C797S-positive resistance to prior EGFR inhibitors, with or without concurrent T790M, a difficult-to-treat population with no
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.
8-K filing — BlossomHill Therapeutics, Inc. (BLSM)
Filed: 2026-09-18 AccNo: 0001193125-26-395031 Size: 239 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Earnings Scheduled For September 18, 2026
Companies Reporting Before The Bell • BlossomHill Therapeutics (NASDAQ:BLSM) is expected to report earnings for its second quarter. Companies Reporting After The Bell This article was generated by Benzinga's